-
Mashup Score: 0
Ghassan K. Abou-Alfa, MD, MBA, Memorial Sloan Kettering Cancer Center, New York, NY, presents the findings of a post-hoc analysis…
Source: VJOncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
Average cumulative relative dose was found to be associated with survival over average relative dose intensity in patients with colorectal cancer, highlighting that obese patients receive lower cumulative doses of adjuvant chemotherapy and therefore may be attributed to their poorer survival outcomes.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
According to results from the OCTOPUS consortium, results showed that 5% increments in ACRD were significantly associated with improvements in disease-free survival. @cslawinski1 @CRUK_MI @myESMO @Annals_Oncology #crcsm #WorldGI2021 https://t.co/XJ8ajWZ68U https://t.co/Wa5MaGRYOt
-
-
Mashup Score: 1
Average cumulative relative dose was found to be associated with survival over average relative dose intensity in patients with colorectal cancer, highlighting that obese patients receive lower cumulative doses of adjuvant chemotherapy and therefore may be attributed to their poorer survival outcomes.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Average Cumulative Relative Adjuvant Chemo Dose Linked With Survival in CRC @cslawinski1 @CRUK_MI @myESMO @Annals_Oncology #crcsm #WorldGI2021 https://t.co/01OZNAS7KG
-
-
Mashup Score: 0Nab-paclitaxel Plus Gemcitabine Boosts Survival for Pancreatic Cancer in 5-year Follow-Up - 3 year(s) ago
Updated overall survival data from the APACT trial suggest improved outcomes for patients with resected pancreatic cancer who receive adjuvant nab-paclitaxel plus gemcitabine despite missing the primary end point in earlier analysis.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Data from the APACT trial suggest improved outcomes for patients w/ resected #pancsm who receive adjuvant nab-paclitaxel plus gemcitabine despite missing the primary end point in earlier analysis @UCSFCancer @UCSFHospitals @myESMO #WorldGI2021 https://t.co/Pc3oMReFeS
-
-
Mashup Score: 1Nab-paclitaxel Plus Gemcitabine Boosts Survival for Pancreatic Cancer in 5-year Follow-Up - 3 year(s) ago
Updated overall survival data from the APACT trial suggest improved outcomes for patients with resected pancreatic cancer who receive adjuvant nab-paclitaxel plus gemcitabine despite missing the primary end point in earlier analysis.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Investigators selected DFS as the primary objective of APACT trial, making it the first adjuvant pancreatic cancer trial to use the independently assessed marker @UCSFCancer @UCSFHospitals @myESMO #WorldGI2021 #pancsm https://t.co/N0He6PmbIw https://t.co/w85U5rBnp4
-
-
Mashup Score: 2Nab-paclitaxel Plus Gemcitabine Boosts Survival for Pancreatic Cancer in 5-year Follow-Up - 3 year(s) ago
Updated overall survival data from the APACT trial suggest improved outcomes for patients with resected pancreatic cancer who receive adjuvant nab-paclitaxel plus gemcitabine despite missing the primary end point in earlier analysis.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Nab-paclitaxel Plus Gemcitabine Boosts Survival for Pancreatic Cancer in 5-year Follow-Up @UCSFCancer @UCSFHospitals @myESMO #WorldGI2021 #pancsm https://t.co/SRe4Hy3kXO
-
-
Mashup Score: 1Nivolumab Combinations Superior to Chemotherapy Alone for Metastatic Esophageal Cancer - 3 year(s) ago
Survival outcomes improved when nivolumab was added to either ipilimumab or chemotherapy versus chemotherapy alone in advanced/metastatic esophageal squamous cell carcinoma
Source: Cancer NetworkCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Preliminary data from the phase 1b GO30103 study indicated that the combination of tiragolumab plus atezolizumab may have promise in patients with heavily pretreated metastatic esophageal cancer. #WorldGI2021 | @genentech https://t.co/U44fZu9xxG
-
-
Mashup Score: 0Support and Mentorship Crucial for Women in Oncology - 3 year(s) ago
Women in oncology report having to face unconscious biases and harassment that limit expectations of who they can be and what they can achieve.
Source: MedscapeCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Learn how it’s possible to prevent biases that hold women in oncology to a higher standard than male counterparts. https://t.co/LWmiSEssoy #WorldGI2021
-
-
Mashup Score: 4Tislelizumab, TTF Studies Poised to Address HCC Questions - 3 year(s) ago
The optimal sequence of therapies in the second- or later-line settings for patients with hepatocellular carcinoma remains unclear.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Tislelizumab is an active and safe PD-1 antibody, for use in the second- and third-line treatment of patients with HCC. Data from RATIONALE 208 showed that the agent had a 13.3% ORR, a PFS of 2.7, and an OS of 13.2 months. @myESMO #WorldGI2021 #hpbcsm https://t.co/b8lIBunPEf https://t.co/FOIMEgzAqO
-
-
Mashup Score: 0GSK2636771/Paclitaxel Combo Demonstrates Early Promise in Advanced PTEN-Deficient Gastric Cancer - 3 year(s) ago
The novel PI3Kß inhibitor GSK2636771 plus paclitaxel led to encouraging clinical activity as well as a tolerable safety profile in patients with PTEN-deficient advanced gastric cancer who progressed following frontline chemotherapy.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
The combination of GSK2636771 and paclitaxel was found to result in a median PFS of 12.1 weeks and OS of 33.4 weeks in patients with PTEN-deficient advanced gastric cancer who progressed following frontline chemotherapy. @myESMO #WorldGI2021 https://t.co/Hc8gTCEdU9 https://t.co/1dwbW22w0F
-
Ghassan K. Abou-Alfa (@GABOUALFA) of @sloan_kettering talks on the impact of prior systemic therapy on PFS in FIGHT-202 👨⚕️🎥 Watch here 👉https://t.co/GjrvCvGhLk👈 @myESMO #WorldGI2021 #GIsm #HPBCsm #STCsm #Oncology